Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial

por Moebus, Volker, Jackisch, Christian, Schneeweiss, Andreas, Huober, Jens, Lueck, Hans-Joachim, du Bois, Andreas, Thomssen, Christoph, Kurbacher, Christian, Kuhn, Walther, Nitz, Ulrike, Runnebaum, Ingo B., Hinke, Axel, Kreienberg, Rolf, Untch, Michael
Publicado 2013

Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial

por Lambertini, Matteo, Agbor-Tarh, Dominique, Metzger-Filho, Otto, Ponde, Noam F, Poggio, Francesca, Hilbers, Florentine S, Korde, Larissa A, Chumsri, Saranya, Werner, Olena, Del Mastro, Lucia, Caparica, Rafael, Moebus, Volker, Moreno-Aspitia, Alvaro, Piccart, Martine J, de Azambuja, Evandro
Publicado 2020